key: cord-0936036-iffirpbw
authors: Zhang, Zhiqin; Zhang, Lian; Zha, Dongqing; Hu, Chun; Wu, Xiaoyan
title: Clinical characteristics and risks of Chinàs 2019 novel coronavirus patients with AKI: a systematic review and meta-analysis
date: 2020-09-02
journal: Ren Fail
DOI: 10.1080/0886022x.2020.1812401
sha: d099d71c317940a77d032bcd78f7c04164b77e36
doc_id: 936036
cord_uid: iffirpbw

nan

The results of the meta-analysis showed that: male (OR:3.43 [1.38, 8 .49], p < 0.05), diabetes (OR:2.63 [1.05, 6 .58], p < 0.05), COPD (OR: 2.98 [1.27, 6 .98], p < 0.05), CKD (OR:3.26 [1.03, 10 .32], p < 0.05), cardiovascular disease (OR: 2.26 [1.21, 4 .21], p < 0.05), and cerebrovascular disease (OR:2.95 [1.38, 6 .32], p < 0.05) were independent risk factors associated with COVID-19 patients with AKI. The meta-analysis revealed no correlation between increased risk of COVID-19 and hypertension, cancer, or chronic liver disease. The discharge rate of COVID-19 patients with AKI was 0.2 [0.11,0.36], p < 0.001 and the fatality rate was 8.78 [5.04,15 .32], p < 0.001.

Four studies included in quantitative synthesis ( Figure 1 ). Data extraction and the evaluation of literature quality were extracted independent ( Table 1 ). The MINORS ( Table 2 ) was used to evaluate bias risk. The Excel was used to analyze the clinical symptoms and examination results. Meta-analysis was performed using Revman5.3.5. When heterogeneity I 2 < 50%, a fixedeffects model was chosen, while when I 2 > 50%, a random-effects model was selected. we consider p < 0.05 as statistical significance (2-sided).

Four studies, including 152 COVID-19 patients with AKI and 637 COVID-19 patients with non-AKI (NAKI), provided the data in terms of male and diabetes. The heterogeneity test showed high heterogeneity among these studies, and random-effects model was used for the meta-analysis. The results find that COVID-19 patients with male (OR:3.43, 95%CI [1.38, 8 .49], p < 0.05) (Figure 2 (A)) and diabetes (OR:2.63, 95%CI [1.05, 6.58], p < 0.05) (Figure 2(B) ) had a higher risk of AKI. nbiased assessment of the study endpoint; -Follow-up period appropriate to the aim of the study; † Loss to follow up less than 5%; ‡ Prospective calculation of the study size. The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The global ideal score being 16 for non-comparative studies. 

Three included studies reported relationships between COPD, CKD, cardiovascular disease, and COVID-19 patients with AKI. No significant heterogeneity was found (I2 ¼ 0) among these trials, so a fixed effect pattern was chosen. The results showed that these risk factors for patients with COVID-19 and AKI. COPD ( 6 .32], p < 0.05) are seen in these meta-analysis respectively. (Figure 3(A-D) ).

Four studies comprising 152 COVID-19 patients with AKI and 637 COVID-19 patients with NAKI evaluated the role of hypertension in patients with COVID-19 and AKI. The meta-analysis showed that patients with the hypertension did not increase the risk of disease progression (OR:1.75, 95%CI[0.86,3.53], p ¼ 0.12) (Figure 4(A) ).The relative risk assessments associated with cancer and chronic liver disease are presented in Figure 4(B,C) . The meta-analysis suggested that there was also no correlation between tumor (OR: (Figure 5 (B)) compared with pure COVID-19 patients, COVID-19 and AKI patients do not have much different on the symptoms [5] [6] [7] . They all have a fever, cough, dizziness, etc. but according to the data in literature, we do focus hypoxia that is easier to emerge in AKI. It means that we need to give oxygen treatment early. In laboratory tests, we also notice PCT, in which many items represent inflammation, could be a effective diagnosis of COVID-19 and AKI (Tables 3,4) .

We made a conclusion that we need pay attention to the degree of hypoxia, inflammatory biomarkers especially PCT of COVID-19 and AKI. And we also should focus on men, diabetes mellitus, COPD, chronic kidney disease (CKD), cardiovascular disease, cerebral blood coronary disease risk factors so that accurate treatment can be made up according to the different condition [8] [9] [10] . The meta has some defects: the articles gathered in this literature are all from China, and the size of the sample is not big enough. So the result needs to be further in-depth study.

None of the authors have any conflicts of interest related to this study.

Zhiqin Zhang http://orcid.org/0000-0002-1807-3668

Clinical features of 62 cases of Coronavirus Disease 2019 complicated with acute renal injury

Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis

Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis

Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China

Risk factors for severe corona virus disease 2019 (COVID-19) patients: a systematic review and meta analysis

Kidney impairment is associated with in-hospital death of COVID-19 patients

Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored